Catalyst Biosciences’ Reverse Merger with GNI Group

Orrick advised Catalyst Biosciences, Inc. on the deal.South San Francisco-based biopharmaceutical company Catalyst Biosciences, Inc. announced its acquisition of the F351 program, a next-generation fibrosis drug, from…

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here
Martina Bellini

Author: Martina Bellini

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here